ADICET BIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.4 USD | +5.26% |
|
-15.15% | -25.93% |
Presenter SpeechUnknown Executive (Executives)Good afternoon, thank you for joining us. On the...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Adicet Bio, Inc. is a clinical stage biotechnology company. The Company is engaged in advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma (NHL). Its pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications. Its pipeline has several additional internal gamma delta T cell therapy programs in discovery and preclinical development for both hematological malignancies and solid tumors.
Calendar
2024-06-05
- Annual General Meeting
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
1.4
USD
Average target price
9.6
USD
Spread / Average Target
+585.71%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -25.93% | 109M | |
| +29.77% | 49.18B | |
| +1.00% | 42.11B | |
| +50.47% | 40.37B | |
| -5.26% | 28.85B | |
| +13.68% | 26.09B | |
| -22.99% | 18.71B | |
| +8.22% | 13.26B | |
| +32.41% | 12.32B | |
| -1.62% | 11.99B |
- Stock Market
- Equities
- ACET Stock
- News Adicet Bio, Inc.
- Transcript : Adicet Bio, Inc. - Special Call